Results 21 to 30 of about 207,511 (311)

Smoking-related interstitial lung disease [PDF]

, 2011
Cigarette smoking has a clear epidemiological association with lung diseases, characterised by chronic inflammation of both the bronchiolar and the interstitial lung compartments.
CERRI, Stefania, F. Luppi, RICHELDI, Luca, SPAGNOLO, Paolo   +3 more
core   +1 more source

Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET/CT: SUVmax versus total lung glycolysis

EJNMMI Research, 2019
Background 18F-FDG PET/CT has proven to be a reliable tool for therapy monitoring in sarcoidosis. Previous PET studies investigated the SUVmax as a marker for disease activity. Total lung glycolysis (TLuG) is a new tool, quantifying the glycolysis of the
Milou C. Schimmelpennink, Adriane D. M. Vorselaars, Marcel Veltkamp, Ruth G. M. Keijsers   +3 more
doaj   +1 more source

Prognostic Predictive Characteristics in Patients With Fibrosing Interstitial Lung Disease: A Retrospective Cohort Study

Frontiers in Pharmacology, 2022
Background: Limited data are available regarding the entire spectrum of interstitial lung disease with a progressive fibrosing feature. We investigated the prevalence and prognostic predictive characteristics in patients with PF-ILD.Methods: This ...
Yuanying Wang, Ziyun Guo, Ruimin Ma, Jingwei Wang, Na Wu, Na Wu, Yali Fan, Qiao Ye, Qiao Ye   +8 more
doaj   +1 more source

The role of nailfold capillaroscopy in interstitial lung diseases - Can it differentiate idiopathic cases from collagen tissue disease associated interstitial lung diseases? [PDF]

, 2015
Introduction: Nailfold capillaroscopy (NFC) is a non-invasive diagnostic test that is mostly used for early diagnosis of collagen tissue diseases (CTDs). We aimed to evaluate whether NFC findings could be a clue for discriminating idiopathic interstitial
Altınışık, Göksel, Balkarli, A., Çakmakçi Karadoğan, D., Çobankara, Veli, Önal, Özgür   +4 more
core   +1 more source

Clusters of comorbidities in fibrotic hypersensitivity pneumonitis

Respiratory Research, 2022
Background Hypersensitivity pneumonitis (HP) is a type of interstitial lung disease (ILD) with a variable disease course and prognosis ranging from inflammatory and self-limiting to irreversible and progressive pulmonary fibrosis.
Thomas Skovhus Prior, Julia Wälscher, Benjamin Gross, Elisabeth Bendstrup, Michael Kreuter   +4 more
doaj   +1 more source

Palliative care for people with non-malignant lung disease: summary of current evidence and future direction [PDF]

, 2013
Background: The physical and psychosocial needs of patients with chronic non-malignant lung disease are comparable to those with lung cancer. This article will focus on chronic obstructive pulmonary disease, interstitial lung disease and cystic fibrosis ...
Boland, Jason, Martin, Jonathan, Ross, Joy R, Ross, Joy R., Wells, Athol U, Wells, Athol U.   +5 more
core   +1 more source

ANXA11 rs1049550 Associates with Löfgren’s Syndrome and Chronic Sarcoidosis

Cells, 2022
Sarcoidosis is an immune mediated granulomatous disease commonly affecting the lungs. Genome wide association studies identified many genomic regions that are shared among multiple immune mediated diseases.
Bekir Karakaya, Joanne J. van der Vis, Marcel Veltkamp, Douwe H. Biesma, Jan C. Grutters, Coline H. M. van Moorsel   +5 more
doaj   +1 more source

Telomerase Reverse Transcriptase Polymorphism rs2736100: A Balancing Act between Cancer and Non-Cancer Disease, a Meta-Analysis

Frontiers in Medicine, 2018
The enzyme telomerase reverse transcriptase (TERT) is essential for telomere maintenance. In replicating cells, maintenance of telomere length is important for the preservation of vital genetic information and prevention of genomic instability.
Reinier Snetselaar, Matthijs F. M. van Oosterhout, Jan C. Grutters, Jan C. Grutters, Coline H. M. van Moorsel, Coline H. M. van Moorsel   +5 more
doaj   +1 more source

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials [PDF]

, 2013
Rationale Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack of consensus on appropriate outcome measures for reliably assessing treatment response.
Antoniou, K, Baughman, RP, Brown, KK, Castelino, FV, Christmann, RB, Christopher-Stine, L, Collard, HR, Cottin, V, Danoff, S, Dellaripa, PF, Denton, CP, Distler, O, Fischer, A, Flaherty, KR, Frankel, S, Highland, KB, Hummers, L, Huscher, D, Khanna, D, Kim, DS, Kowal-Bielecka, OM, LeSage, D, Lynch, DA, Matteson, EL, Merkel, PA, Miller, FW, Mittoo, S, Oddis, CV, Phillips, K, Pittrow, D, Proudman, SM, Richeldi, L, Ryu, JH, Saketkoo, LA, Sandorfi, N, Sarver, C, Seibold, JR, Shah, AA, Strand, V, Swigris, J, Wells, AU   +40 more
core   +1 more source

In-hospital mortality following surgical lung biopsy for interstitial lung disease in the USA: 2000-2011 [PDF]

, 2016
Rationale: Surgical lung biopsy can help to determine a specific diagnosis in interstitial lung disease, but has associated risks. Most currently available mortality data are derived from case series and may not be generalizable to broader populations.
Fogarty, Andrew W., Hubbard, Richard B., Hutchinson, John P., McKeever, Tricia M.   +3 more
core   +1 more source